Short Communication: Lamivudine Resistance of HIV Type 1 Does Not Delay Development of Resistance to Nonnucleoside HIV Type 1-Specific Reverse Transcriptase Inhibitors as Compared with Wild-Type HIV Type 1

1998 ◽  
Vol 14 (3) ◽  
pp. 249-253 ◽  
Author(s):  
HEIDI JONCKHEERE ◽  
MYRIAM WITVROUW ◽  
ERIK DE CLERCQ ◽  
JOZEF ANNÉ
1997 ◽  
Vol 13 (7) ◽  
pp. 533-543 ◽  
Author(s):  
JAMES E. DRUMMOND ◽  
PHOEBE MOUNTS ◽  
ROBERT J. GORELICK ◽  
JOSE R. CASAS-FINET ◽  
WILLIAM J. BOSCHE ◽  
...  

1996 ◽  
Vol 40 (12) ◽  
pp. 2887-2890 ◽  
Author(s):  
R W Shafer ◽  
M A Winters ◽  
A K Iversen ◽  
T C Merigan

The observation that human immunodeficiency virus type 1 (HIV-1) mutations conferring resistance to one reverse transcriptase (RT) inhibitor may suppress resistance to other RT inhibitors provides a rationale for treating HIV-1 with certain RT inhibitor combinations. We examined phenotypic and genotypic changes during culture of a multinucleoside (zidovudine, didanosine, zalcitibine, and stavudine)-resistant HIV-1 strain with and without additional RT inhibitors (nevirapine and lamivudine). The development of nevirapine or lamivudine resistance by the multinucleoside-resistant strain was not accompanied by a reduction in zidovudine or didanosine resistance.


2010 ◽  
Vol 26 (8) ◽  
pp. 895-899
Author(s):  
Uma Shanmugasundaram ◽  
Suniti Solomon ◽  
Kailapuri G. Murugavel ◽  
Kumarasamy Nagalingeswaran ◽  
Sunil S. Solomon ◽  
...  

2010 ◽  
Vol 26 (10) ◽  
pp. 1093-1096 ◽  
Author(s):  
Uma Shanmugasundaram ◽  
Suniti Solomon ◽  
Vidya Madhavan ◽  
Murugavel G. Kailapuri ◽  
Kumarasamy Nagalingeswaran ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document